Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q7Z4J2
UPID:
GL6D1_HUMAN
Alternative names:
Galactosyltransferase family 6 domain-containing 1
Alternative UPACC:
Q7Z4J2
Background:
Putative glycosyltransferase 6 domain-containing protein 1, also known as Galactosyltransferase family 6 domain-containing 1, is a protein encoded by the gene with the accession number Q7Z4J2. Its specific functions in cellular processes are yet to be fully elucidated. However, as a member of the glycosyltransferase family, it is likely involved in the modification of proteins and lipids by adding sugar moieties, a critical process for cellular function and signaling.
Therapeutic significance:
Understanding the role of Putative glycosyltransferase 6 domain-containing protein 1 could open doors to potential therapeutic strategies. Its involvement in glycosylation processes makes it a candidate for research in diseases where protein and lipid modification play a crucial role.